-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
-
Summary
-
Kymera Therapeutics, Inc. quarterly/annual Depreciation history and growth rate from Q3 2019 to Q2 2025.
- Kymera Therapeutics, Inc. Depreciation for the quarter ending June 30, 2025 was $1.7M, a 10.5% decline year-over-year.
- Kymera Therapeutics, Inc. Depreciation for the twelve months ending June 30, 2025 was $7.3M, a 40.4% increase year-over-year.
- Kymera Therapeutics, Inc. annual Depreciation for 2024 was $7.4M, a 106% increase from 2023.
- Kymera Therapeutics, Inc. annual Depreciation for 2023 was $3.6M, a 20% increase from 2022.
- Kymera Therapeutics, Inc. annual Depreciation for 2022 was $3M, a 25% increase from 2021.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)